Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
---|
02/27/2013 | CN102947336A Methods of treating diabetes with dll4 antagonists |
02/27/2013 | CN102947335A Anti-polyubiquitin antibodies and methods of use |
02/27/2013 | CN102947334A Antibodies for treatment of clostridium difficile-associated infection and disease |
02/27/2013 | CN102947333A 抗体组合物 Antibody composition |
02/27/2013 | CN102946906A Production of heteromultimeric proteins |
02/27/2013 | CN102946905A Cgrp antibodies |
02/27/2013 | CN102946904A Arthritis treatment |
02/27/2013 | CN102946903A High concentration antibody formulations |
02/27/2013 | CN102946902A Bispecific antibodies |
02/27/2013 | CN102946901A Conjugates utilizing platform technology for stimulating immune response |
02/27/2013 | CN102946900A Vaccines for pandemic influenza |
02/27/2013 | CN102946899A Pharmaceutical composition |
02/27/2013 | CN102946867A Compoisitons comprising polyglutamic acid nanoparticles and polypeptides such as cd40 agonists |
02/27/2013 | CN102946861A Concentrated protein formulations and uses thereof |
02/27/2013 | CN102943087A Novel subunit vaccine against rabbit hemorrhagic disease virus and preparation method thereof |
02/27/2013 | CN102942631A Humanized anti-cmet antagonists |
02/27/2013 | CN102942629A Humanized antibody for resisting severe fever with thrombocytopenia syndrome bunyavirus (SFTSV) |
02/27/2013 | CN102942614A Preparation method and application of high-purity polysaccharopeptide |
02/27/2013 | CN102940886A Biological barrier penetrating agent and preparation method thereof |
02/27/2013 | CN102940883A Therapeutic composition to improve the effect of the therapy with anti-epidermal growth factor receptor antibodies |
02/27/2013 | CN102940875A Paa protein, antibody prepared from the same, and application thereof |
02/27/2013 | CN102268410B Newcastle disease virus heat-resistant attenuated strain adapted to baby hamster kidney passage cell and preparation method and application thereof |
02/27/2013 | CN102250843B Genetic engineering marked attenuated vaccine strain of porcine reproductive and respiratory syndrome virus and application thereof |
02/27/2013 | CN102247600B Method for preparing diluent for pseudorabies live vaccine |
02/27/2013 | CN102154219B Swine influenza A H1N1 virus and use thereof |
02/27/2013 | CN101947323B Gram negative bacterium vaccine and preparation method thereof |
02/27/2013 | CN101613398B Surface lipoprotein of streptococcus suis type-2, preparation method thereof and application |
02/27/2013 | CN101463084B Gene engineering monoclonal antibody combined with A-beta oligomer specificity |
02/27/2013 | CN101220370B Bifidobacteria-bacillus coli shuttle expression vector, preparation method and application thereof |
02/26/2013 | US8383806 Method of reversing carboplatin resistance by inhibition of HGFIN |
02/26/2013 | US8383802 Nucleic acids encoding antibodies that bind factor D |
02/26/2013 | US8383790 Modified surface antigen |
02/26/2013 | US8383788 For therapy of cancer or tumorous growth |
02/26/2013 | US8383781 Anti-NIK antibodies and uses thereof |
02/26/2013 | US8383780 Antibodies to TGFβ |
02/26/2013 | US8383777 13-transmembrane protein expressed in prostate cancer |
02/26/2013 | US8383775 Cytokine zalpha11 ligand |
02/26/2013 | US8383769 Peptides for inhibiting chemokine binding to chemokine receptors |
02/26/2013 | US8383767 Immunogenic protein carrier containing an antigen presenting cell binding domain and a cysteine-rich domain |
02/26/2013 | US8383371 Nucleic acid construct containing a nucleic acid derived from the genome of hepatitis C virus (HCV) of genotype 2a, and a cell having such nucleic acid construct introduced therein |
02/26/2013 | US8383358 Use of 2 anti-SPARC antibodies to predict response to melanoma chemotherapy |
02/26/2013 | US8383354 Diagnostic method for atherosclerosis |
02/26/2013 | US8383153 Poly(amidoamine) oligomer hydrogel for drug delivery and drug carrier using the same |
02/26/2013 | US8383133 Conjugates of Plasmodium falciparum surface proteins as malaria vaccines |
02/26/2013 | US8383132 Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use |
02/26/2013 | US8383131 Porcine reproductive and respiratory syndrome isolates and methods of use |
02/26/2013 | US8383129 Employment of rotavirus proteins, derived proteins and peptides for the modulation of tissue permeability |
02/26/2013 | US8383126 Bacterial pheromones and uses thereof |
02/26/2013 | US8383125 Antimicrobial protein |
02/26/2013 | US8383124 Mobilization of hematopoietic stem cells |
02/26/2013 | US8383123 Method of treatment targeting HEPSIN |
02/26/2013 | US8383122 Process for preparing purified drug conjugates |
02/26/2013 | US8383121 Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus H5-subtype or N1-subtype and uses thereof |
02/26/2013 | US8383120 Concomitant treatment of rheumatoid arthritis with anti-TNF-alpha antibodies and methotrexate |
02/26/2013 | US8383119 Biological substance nesfatin and its related substances and uses thereof |
02/26/2013 | US8383118 Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1 |
02/26/2013 | US8383117 CD44E tumor specific antibody |
02/26/2013 | US8383116 Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy |
02/26/2013 | US8383115 Engineered scFv against bovine herpes virus type I |
02/26/2013 | US8383113 Anti-ADDL antibodies and uses thereof |
02/26/2013 | US8383112 Targeting VEGF-B regulation of fatty acid transporters to modulate human diseases |
02/26/2013 | US8383111 Inotropic antibodies and therapeutic uses thereof |
02/26/2013 | US8383110 Modulators of Candida hyphal morphogenesis and uses thereof |
02/26/2013 | US8383109 Optimized Fc variants and methods for their generation |
02/26/2013 | US8383108 Therapeutic uses of monoclonal antibodies to the angiotensin-II type 1 receptor |
02/26/2013 | US8383107 Single domain brain-targeting antibody fragments derived from llama antibodies |
02/26/2013 | US8383106 Materials and methods for improved immunoglycoproteins |
02/26/2013 | US8383100 Method to treat and prevent skin diseases with Porifera-based therapeutic compositions treating and preventing skin diseases |
02/26/2013 | US8383096 Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine |
02/26/2013 | US8383084 Modify surface of spore to increase adherence to phagocyte; activate phagocytic cells; ingest spore with phagocyte; killing spore by blocking spore-induced phagocyte cell death; increase activation, production of antimicrobial and cytocidal agents endogenous nitric oxide, inflammatory cytokines |
02/26/2013 | US8383081 Anti-CD74 immunoconjugates and methods of use |
02/26/2013 | CA2674885C Anti-ige vaccines |
02/26/2013 | CA2674837C Anti-ige vaccines |
02/26/2013 | CA2524399C Optimized fc variants and methods for their generation |
02/26/2013 | CA2509973C Multi-antigenic alphavirus replicon particles and methods |
02/26/2013 | CA2493406C Gm-negative ehv-mutants without heterologous elements |
02/26/2013 | CA2492068C Assays for assembly of ebola virus nucleocapsids |
02/26/2013 | CA2430115C Recombinant rsv virus expression systems and vaccines |
02/26/2013 | CA2389644C A novel polypeptide hormone phosphatonin |
02/26/2013 | CA2327586C Fap.alpha.-specific antibody with improved producibility |
02/25/2013 | CA2750419A1 Novel treatment, prevention or diagnosis of health problems |
02/21/2013 | WO2013026054A2 Production of infectious rna viruses in yeast |
02/21/2013 | WO2013026004A2 Antibodies that bind integrin alpha-v beta-8 |
02/21/2013 | WO2013025936A1 Detection and treatment of metastatic disease |
02/21/2013 | WO2013025925A1 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors |
02/21/2013 | WO2013025853A1 Neuregulin antibodies and uses thereof |
02/21/2013 | WO2013025834A2 Compositions and methods related to antibodies to staphylococcal protein a |
02/21/2013 | WO2013025817A1 Use of neuregulin-4 for treatment of inflammatory bowel disease and necrotizing enterocolitis |
02/21/2013 | WO2013025545A2 Drug delivery systems and method of reducing foal infection by treating mares with gallium salts |
02/21/2013 | WO2013025538A2 Compositions, methods and uses of alpha 1-antitrypsin for early intervention in bone marrow transplantation and treatment of graft versus host disease |
02/21/2013 | WO2013025479A1 Jaml specific binding agents, antibodies, and uses related thereto |
02/21/2013 | WO2013025467A2 Methods of treating hematological proliferative disorders by targeting epha3 expressed on aberrant vasculature in bone marrow |
02/21/2013 | WO2013025446A2 Anti-fzd10 monoclonal antibodies and methods for their use |
02/21/2013 | WO2013024905A1 Combination drug of antibody against lipopolysaccharide of pseudomonas aeruginosa and antibacterial agent |
02/21/2013 | WO2013024859A1 Molecular mimic mucosal aids vaccine |
02/21/2013 | WO2013024289A1 Livestock improvement |
02/21/2013 | WO2013024157A2 Combinations of host targeting agents for the treatment and the prevention of hcv infection |
02/21/2013 | WO2013024156A2 Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection |
02/21/2013 | WO2013024155A1 Combinations of anti-hcv-entry factor antibodies and direct acting antivirals for the treatment and the prevention of hcv infection |
02/21/2013 | WO2013024113A1 Influenza h5 vaccines |